The head of the U.S. agency in charge of AIDS research says scientists need to go back to basics to find a vaccine against the HIV virus.
Dr. Anthony S. Fauci of the National Institute of Allergy and Infectious Diseases said the agency will re-evaluate the use of the $1.5 billion it spends on AIDS research, The New York Times reported Wednesday. He said more basic laboratory research is needed to understand the way the body and experimental vaccines respond to HIV.
"There is not an immediate solution to the problem," Fauci told the newspaper at a summit Tuesday in Bethesda, Md., to discuss fallout from last year's failure of the most promising candidate for an HIV vaccine.
Fauci rejected the AIDS Health Care Foundation's call for the suspension of money for HIV vaccine research in favor of increased AIDS prevention efforts. "Under no circumstances will we stop AIDS vaccine research," he said.
Copyright 2008 by United Press International
Related stories:
NIAID creates HIV vaccine discovery branch
To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS).
New HIV browser gives researchers access to valuable data from vaccine trials
A new HIV data browser developed by the University of California, Santa Cruz, and the nonprofit organization Global Solutions for Infectious Diseases (GSID) will give researchers access to a wealth of data collected during clinical trials of an AIDS vaccine. Although the vaccine did not succeed in preventing infections, the clinical trial generated a huge amount of valuable data for researchers studying how the virus evolves and causes new infections.
Regulatory B cells exist -- and pack a punch
Researchers at Duke University Medical Center have uncovered definitive evidence that a small but potent subset of immune system B cells is able to regulate inflammation.
Study finds unique HIV vaccine formula elicits strong immune responses
Today, Advanced BioScience Laboratories, Inc. and the University of Massachusetts Medical School report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
HIV infection stems from few viruses
A new study reveals the genetic identity of human immunodeficiency virus (HIV), the version responsible for sexual transmission, in unprecedented detail.
Major shift in HIV prevention priorities needed
According to a new policy analysis led by researchers at the Harvard School of Public Health (HSPH) and the University of California, Berkeley, the most common HIV prevention strategies—condom promotion, HIV testing, treatment of other sexually transmitted infections (STIs), vaccine and microbicide research, and abstinence—are having a limited impact on the predominantly heterosexual epidemics found in Africa. Furthermore, some of the assumptions underlying such strategies—such as poverty or war being major causes of AIDS in Africa—are unsupported by rigorous scientific evidence.
Scientists lose hope over AIDS vaccine
A survey of leading U.S. and British AIDS researchers said many scientists see little hope of an effective vaccine against HIV in the near future.
NIAID describes research priorities to fight drug-resistant tuberculosis
Tuberculosis (TB) has long been one of the world’s great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.